These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15006288)

  • 1. Clinical neuropharmacology of drugs of abuse: a comparison of drug-discrimination and subject-report measures.
    Kelly TH; Stoops WW; Perry AS; Prendergast MA; Rush CR
    Behav Cogn Neurosci Rev; 2003 Dec; 2(4):227-60. PubMed ID: 15006288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
    Johnson MW; Suess PE; Griffiths RR
    Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teenagers are right--parents do not know much: an analysis of adolescent-parent agreement on reports of adolescent substance use, abuse, and dependence.
    Fisher SL; Bucholz KK; Reich W; Fox L; Kuperman S; Kramer J; Hesselbrock V; Dick DM; Nurnberger JI; Edenberg HJ; Bierut LJ
    Alcohol Clin Exp Res; 2006 Oct; 30(10):1699-710. PubMed ID: 17010137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditioned and sensitized responses to stimulant drugs in humans.
    Leyton M
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Nov; 31(8):1601-13. PubMed ID: 17888557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are clinical impressions of adolescent substance use accurate?
    Wilson CR; Sherritt L; Gates E; Knight JR
    Pediatrics; 2004 Nov; 114(5):e536-40. PubMed ID: 15520086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a clinical methodology for neuropsychopharmacological research.
    Ban TA
    Neuropsychopharmacol Hung; 2007 Jun; 9(2):81-90. PubMed ID: 17970531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of imaging in the early development of neuropharmacological drugs: a survey of approved NDAs.
    Uppoor RS; Mummaneni P; Cooper E; Pien HH; Sorensen AG; Collins J; Mehta MU; Yasuda SU
    Clin Pharmacol Ther; 2008 Jul; 84(1):69-74. PubMed ID: 18563070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advantages and limitations of Triage DOA screening in clinical and forensic drug testing].
    Moriya F
    Chudoku Kenkyu; 2008 Jul; 21(3):273-83. PubMed ID: 18712071
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients.
    Adams LL; Gatchel RJ; Robinson RC; Polatin P; Gajraj N; Deschner M; Noe C
    J Pain Symptom Manage; 2004 May; 27(5):440-59. PubMed ID: 15120773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing abuse liability during drug development: changing standards and expectations.
    Schoedel KA; Sellers EM
    Clin Pharmacol Ther; 2008 Apr; 83(4):622-6. PubMed ID: 18212799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychoactive drug abuse in older adults.
    Simoni-Wastila L; Yang HK
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):380-94. PubMed ID: 17296542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral fluid testing: new technology enables drug testing without embarrassment.
    Cone EJ
    J Calif Dent Assoc; 2006 Apr; 34(4):311-5. PubMed ID: 16900989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study.
    Peirce JM; Petry NM; Stitzer ML; Blaine J; Kellogg S; Satterfield F; Schwartz M; Krasnansky J; Pencer E; Silva-Vazquez L; Kirby KC; Royer-Malvestuto C; Roll JM; Cohen A; Copersino ML; Kolodner K; Li R
    Arch Gen Psychiatry; 2006 Feb; 63(2):201-8. PubMed ID: 16461864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substance abuse in pregnant women: making improved detection a good clinical outcome.
    Araojo R; McCune S; Feibus K
    Clin Pharmacol Ther; 2008 Apr; 83(4):520-2. PubMed ID: 18349872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral fluid collection: the neglected variable in oral fluid testing.
    Crouch DJ
    Forensic Sci Int; 2005 Jun; 150(2-3):165-73. PubMed ID: 15899565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor and item-response analysis DSM-IV criteria for abuse of and dependence on cannabis, cocaine, hallucinogens, sedatives, stimulants and opioids.
    Gillespie NA; Neale MC; Prescott CA; Aggen SH; Kendler KS
    Addiction; 2007 Jun; 102(6):920-30. PubMed ID: 17523987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for toxicological investigation of drug impaired driving.
    Farrell LJ; Kerrigan S; Logan BK
    J Forensic Sci; 2007 Sep; 52(5):1214-8. PubMed ID: 17680796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical techniques for drug detection in oral fluid.
    Lillsunde P
    Ther Drug Monit; 2008 Apr; 30(2):181-7. PubMed ID: 18367978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Date-rape drugs scene in Poland.
    Adamowicz P; Kała M
    Przegl Lek; 2005; 62(6):572-5. PubMed ID: 16225127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for drugs in oral fluid: illicit drug use and drug driving in a sample of Queensland motorists.
    Davey J; Leal N; Freeman J
    Drug Alcohol Rev; 2007 May; 26(3):301-7. PubMed ID: 17454020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.